What Are Pfizer's Prospects In Obesity Pill Market? Analysts Say Optimism, Cautiousness Surround With Data Awaited Next Year
Portfolio Pulse from Vandana Singh
Pfizer Inc (PFE) is targeting the obesity pill market with its experimental drug, danuglipron, aiming for a $10 billion segment. Pfizer discontinued another candidate, lotiglipron, due to unsatisfactory Phase 1 results. Competitors Eli Lilly (LLY) and Novo Nordisk (NVO) have set high standards in the weight loss drug industry. Pfizer's upcoming phase two trial data for danuglipron is eagerly awaited by investors, with results expected by year-end for the twice-daily pill and early next year for a once-daily version. Despite a 40% share price drop, Pfizer's CEO sees a $90 billion market potential for GLP-1s. Analysts highlight the need for Pfizer's pill to achieve a 14%-15% weight loss to compete with Eli Lilly's product. PFE shares were down 1.44% at $29.06 on the last check Monday.
November 13, 2023 | 7:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer is developing danuglipron for the obesity market, with phase two trial data expected soon. Positive results could boost investor confidence and share price, which has recently dropped by 40%.
Pfizer's focus on the obesity drug market with danuglipron is a significant move, especially with the anticipation of trial data. Positive results could lead to a rebound in the stock price, which has suffered recently. The importance is high due to the potential market size and the need for Pfizer to maintain competitiveness with Eli Lilly and Novo Nordisk.
CONFIDENCE 75
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Eli Lilly's success with Mounjaro sets a high benchmark for Pfizer's danuglipron. Analysts suggest Pfizer needs to match or exceed a 14%-15% weight loss to stay competitive.
Eli Lilly is mentioned as a key competitor in the obesity drug market, with its product Mounjaro setting a benchmark for effectiveness. While the news is more focused on Pfizer, Eli Lilly's relevance comes from its competitive position, which could be impacted by Pfizer's trial outcomes.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Novo Nordisk's products Wegovy and Ozempic contribute to the industry's success, which Pfizer aims to join with its own obesity drug, danuglipron.
Novo Nordisk is identified as a leading company in the weight loss drug market, which Pfizer is attempting to enter. The impact on Novo Nordisk is indirect and depends on the success of Pfizer's trials, hence the neutral score.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 60